SAN DIEGO, Feb. 11 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA)
today announced that it is implementing certain initiatives designed to better
focus its activities on the continuing development of products from its
iDiscovery(TM) technologies. These products include its information-rich
Chem.Folio(R) combinatorial libraries for screening against biological targets
and its IDEA(TM) predictive models for the prediction and selection of
compounds with essential drug-like characteristics for further development.
Trega's iDiscovery technologies are intended to increase the chance of success
and speed the pharmaceutical discovery and development process.
Consistent with this strategic focus, Trega has decided that it will no
longer support in-house drug discovery that is not funded by a collaborator.
Trega is currently carrying out a collaborative program in the area of
diabetes, obesity, and syndrome X, funded by Novartis. The Company is seeking
funded relationships for its other programs.
Trega Biosciences is an information-driven company focused on accelerating
drug discovery from disease targets to clinical candidates through its
iDiscovery(TM) technologies comprised of small molecule combinatorial
chemistry, high throughput screens and predictive models to rapidly create
novel drug candidates having greater chances of clinical success. Trega's
iDiscovery technologies span the drug discovery process, beginning with
synthesizing novel compounds to providing uniquely qualified drug leads to the
pharmaceutical and life-science industries.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including whether any collaboration will be
successful, any additional collaborations or alliances will be agreed to,
formed or expanded, whether further Chem.Folio(R) libraries can be
successfully developed and sold, whether the IDEA(TM) models can be
successfully developed and commercialized, whether regulatory approvals can be
obtained for products discovered and developed, if any, the impact of
competitive products and pricing, whether any other corporate collaborations
or alliances will be successful, and other risks detailed from time to time in
Trega's Securities and Exchange Commission filings. These forward-looking
statements represent Trega's judgment as of the date of this release. Actual
results may differ materially from those projected. Trega disclaims, however,
any intent or obligation to update these forward-looking statements.
For copies of press releases and additional information, please consult
Trega's web site at http://www.trega.com or by PR Newswire's fax-on-demand
service at 1-800-758-5804, extension 374050.
SOURCE Trega Biosciences, Inc.
 back to top
Related links:
http://www.trega.com
Company News On-Call:
http://www.prnewswire.com/comp/374050.html or fax,
800-758-5804, ext. 374050
CONTACT:
Gerard A. Wills, Vice President Finance &
CFO, 858-410-6695, or Cynthia Reindal, Corp. Communications &
Investor Relations, 858-410-6601, both of Trega Biosciences, Inc.
|
